1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Fosun International Limited
  6. News
  7. Summary
    656   HK0656038673

FOSUN INTERNATIONAL LIMITED

(656)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Fosun International : Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets

01/18/2022 | 10:22pm EDT
Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets
Release Time:2022-01-18Author:Source: Pageviews:
SHANGHAI, CHINA and, NEW YORK, USA, January 11, 2022 -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK), a leading innovation-driven international healthcare group in China and Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery and development company, entered into a collaboration agreement to advance the discovery and development of drugs targeting a number of different targets globally through the use of AI technology.

This strategic collaboration includes an AI-driven drug discovery research and development (R&D) collaboration on four biological targets, as well as the co-development of Insilico's QPCTL program. Insilico will receive a total upfront payment of $13 million for the R&D collaboration projects and the co-development of the QPCTL program, potential milestone-based payments, and share commercialization profits from the QPCTL program. In addition, Fosun Pharma will make an equity investment in Insilico.

"We are pleased to enter into strategic collaboration with Insilico. Fosun Pharma is committed to promoting innovative R&D, and is oriented towards fulfilling unmet clinical needs and improving products' accessibility. We look forward to working with Insilico to leverage the technological and clinical development strengths of both companies, jointly improving the efficiency of innovative drug R&D, and benefiting more patients worldwide," said Yifang Wu, Chairman and CEO of Fosun Pharma.

The collaboration aims to combine Insilico's end-to-end AI-driven drug discovery platforms and Fosun Pharma's clinical development and commercial expertise to discover and develop a portfolio of novel therapeutics. Pursuant to the collaboration agreement, Insilico will take responsibility for delivering a preclinical candidate for the QPCTL program and advancing it to IND stage, after which, Fosun Pharma will then conduct human clinical studies and co-develop the candidate globally. In parallel, Fosun Pharma's R&D team will nominate four therapeutic targets to be assessed by Insilico's AI platform and R&D team, who are responsible of advancing drug candidates to IND stage.

As part of the collaboration, Fosun Pharma will secure access to Insilico's PandaOmics and Chemistry42 platforms in order to advance Fosun Pharma's internal AI-powered discovery and development efforts.

"In partnering with Fosun Pharma, a leading pharmaceutical company, we begin a new era of AI-powered end-to-end drug discovery and development as human-machine collaboration becoming the new normal in precision drug discovery and development. We previously demonstrated that AI can be used to discover novel targets and generate novel molecules that can be tested in humans in record time. Now, we are partnering with one of the leading scientific teams in the pharmaceutical industry to take this technology to the next level for the benefit of patients worldwide", said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine.

About Fosun Pharma


Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196.SH, 02196.HK) is a leading innovation-driven international healthcare group in China. Fosun Pharma strategically operates businesses in the pharmaceutical and health industry, including pharmaceutical manufacturing, medical devices and medical diagnosis, and healthcare services. Through equity participation in Sinopharm Co., Ltd., Fosun Pharma's business extends to pharmaceutical distribution and retail.

Fosun Pharma takes pharmaceutical manufacturing as its core business and sticks to innovative research and development. Through in-house R&D, co-development, in-licensing and incubation, Fosun Pharma had established platforms for small molecule innovative drugs, antibody drugs and cell therapy, focusing on major therapeutic areas, including oncology, immunology, "4 hypers" (hypertension, hyperlipidemia, hyperglycemia and hyperuricemia) and their complications, as well as central nervous system. In the meantime, Fosun Pharma keeps close track of cutting-edge technologies, such as targeted protein degradation, RNA, oncolytic virus and gene therapy to enhance its innovation ability.

Looking forward, under guidance of 4IN strategy (Innovation, Internationalization, Integration and Intelligentization), Fosun Pharma practices innovation and transformation, integrated operation and steady development, as well as the concept of sustainable development. Fosun Pharma is committed to becoming the first-class enterprise in the global mainstream healthcare industry.

For more information, please visit: www.fosunpharma.com.

Fosun Pharma Forward-looking statements


This press release contains forward-looking statements. All statements other than statements of historical fact contained in this press release, including, without limitation, the discussions of the Company's business strategies and expectations concerning future operations, margins, profitability, liquidity and capital resources, the future development of the Company's industry and the future development of the general economy of the Company's key markets and any statements preceded by, followed by or that include words and expressions such as "expect", "seek", "believe", "plan", "intend", "estimate", "project", "anticipate", "may", "will", "would" and "could" or similar words or statements, as they relate to the Company or its management, are intended to identify forward-looking statements. These statements are subject to certain known and unknown risks, uncertainties and assumptions, which may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Accordingly, you should not place undue reliance on any forward-looking information. Subject to the requirements of applicable laws, rules and regulations, the Company does not have any and undertakes no obligation to update or otherwise revise the forward- looking statements in this press release, whether as a result of new information, future events or developments or otherwise. In this press release, statements of or references to the Company's intentions are made as of the date of this press release. Any such intentions may change in light of future developments. All forward-looking statements contained in this press release are qualified by reference to the cautionary statements set out above.

About Insilico Medicine

Insilico Medicine, an end-to-end AI-driven drug discovery and development company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. Insilico Medicine has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system (CNS) diseases and aging-related diseases. For more information, visit www.insilico.com.

Disclaimer

Fosun International Limited published this content on 18 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 January 2022 03:21:03 UTC.


© Publicnow 2022
All news about FOSUN INTERNATIONAL LIMITED
05/23Robot++ announced that it has received $15 million in funding from Meituan, Fosun Inter..
CI
05/23RobotPlusPlus announced that it has received $15 million in funding from Meituan, Fosun..
CI
05/05Metaverse, web3 and football club valuations
AQ
04/29FOSUN INTERNATIONAL : 2021 ESG Report Highlights in a Glance
PU
04/28Fosun International to Vote June 2 on New Share Issuance, Buyback Plans
MT
04/27FOSUN INTERNATIONAL : CSR Report 2021
PU
04/27FOSUN INTERNATIONAL : Sustain Resilience and Develop Business for Good to Empower the Futu..
PU
04/25FOSUN INTERNATIONAL : World Malaria Day | Fosun Pharma's Self-Developed Artemisinin Series..
PU
04/19XU XIAOLIANG, CO-CEO OF FOSUN INTERN : Fosun, a Synonym for Happiness
PU
04/14CHEN QIYU, CO-CEO OF FOSUN INTERNATI : Fosun's ESG Journey to a Happier Life
PU
More news
Analyst Recommendations on FOSUN INTERNATIONAL LIMITED
More recommendations
Financials
Sales 2022 174 B 25 871 M 25 871 M
Net income 2022 12 758 M 1 893 M 1 893 M
Net Debt 2022 135 B 20 084 M 20 084 M
P/E ratio 2022 4,29x
Yield 2022 5,05%
Capitalization 54 514 M 8 090 M 8 090 M
EV / Sales 2022 1,09x
EV / Sales 2023 1,04x
Nbr of Employees 96 000
Free-Float 27,1%
Chart FOSUN INTERNATIONAL LIMITED
Duration : Period :
Fosun International Limited Technical Analysis Chart | 656 | HK0656038673 | MarketScreener
Technical analysis trends FOSUN INTERNATIONAL LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 6,56 CNY
Average target price 9,30 CNY
Spread / Average Target 41,8%
EPS Revisions
Managers and Directors
Qi Yu Chen Co-Chief Executive Officer & Executive Director
Xiao Liang Xu Co-Chief Executive Officer & Executive Director
Ping Gong Chief Financial Officer & Executive Director
Hou Lin Zhang Co-Chief Financial Officer & Senior Vice President
Li Gang Zhang Co-CFO & GM-Financial Management
Sector and Competitors
1st jan.Capi. (M$)
FOSUN INTERNATIONAL LIMITED-9.16%8 090
CHUBB LIMITED7.44%88 482
ALLIANZ SE-4.26%86 554
MARSH & MCLENNAN COMPANIES-12.27%78 970
ZURICH INSURANCE GROUP LTD10.31%68 161
BAJAJ FINSERV LIMITED-24.38%25 571